Cargando…
2718. Prevalence of Infections Following Anti-CD30 Targeted Chimeric Antigen Receptor T-cell Therapy for Relapsed and Refractory Lymphoma
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or refractory hematologic malignancies. Clinical trials have demonstrated anti-CD30 CAR T-cell efficacy in patients with CD30+ malignancies such as Hodgkin lymphoma, but little is known about post...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677856/ http://dx.doi.org/10.1093/ofid/ofad500.2329 |